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Abstract
Background: Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease
are poor. Thus, new therapeutic strategies are urgently required.
Methods: In this retrospective study, we analyzed the clinical outcomes of consecutive patients with metastatic
vaginal or vulvar cancer who were referred to a phase I trial clinic between January 2006 and December 2013.
Demographic and clinical data were obtained from patients’ electronic medical records.
Results: Patients with metastatic vaginal (n = 16) and vulvar (n = 20) cancer who were referred for phase I trial
therapy had median overall survival durations of 6.2 and 4.6 months, respectively. Among those who underwent
therapy (n = 27), one experienced a partial response and three experienced stable disease for at least 6 months.
Patients with a body mass index ≥30 had a significantly longer median overall survival duration than did those with
a body mass index <30 (13.2 months versus 4.4 months, p = 0.04). Preliminary data revealed differences in molecular
profiling between patients with advanced vaginal cancer and those with advanced vaginal cancer.
Conclusions: Metastatic vaginal and vulvar cancers remain to be difficult-to-treat diseases with poor clinical outcomes.
The currently available phase I trial agents provided little meaningful clinical benefits. Understanding these tumors’
molecular mechanisms may allow us to develop more effective therapeutic strategies than are currently available
regimens.
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Background
Vaginal and vulvar cancers comprise approximately 8 %
of all malignant neoplasms of the female genital tract:
approximately 3,000 vaginal cancers and 4,500 vulvar
cancers are diagnosed annually in the United States [1].
Most of these tumors are squamous cell carcinomas, but
melanoma, sarcoma, adenocarcinoma, and other histo-
logical types also occur [2–6]. All vaginal and vulvar
cancers are associated with similar risk factors: cigarette
smoking, human papillomavirus infection, and a history
of other gynecological malignancies [7, 8]. Early-stage
vaginal and vulvar cancer can be cured, but if the disease
is not amenable to radical local excision or curative
chemoradiation therapy [9–11], patients with recurrent
or metastatic vaginal or vulvar cancers have a poor prog-
nosis [12, 13]. Palliative systemic therapy results in lim-
ited clinical benefit [14].
The overall poor prognosis of these patients warrants
the development of novel therapeutic regimens [15].
Therefore, we conducted a retrospective chart review to
identify the demographic characteristics and major
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clinical outcomes, such as mutational status, clinical re-
sponse, and survival duration, of patients with metastatic
vaginal or vulvar cancer who were referred to a desig-
nated phase I trial clinic. These data may lead to the




We included all consecutive patients with metastatic or
recurrent vaginal or vulvar carcinoma who were referred
to the Department of Investigational Cancer Therapeutics
(a phase I clinical trials program) at The University of
Texas MD Anderson Cancer Center between January 1,
2006, and December 31, 2013 in this retrospective chart
review. Follow-up was defined as the time of the initial
phase I clinic visit until death or the last date of the study,
censored on August 8, 2014. This study was conducted in
accordance with MD Anderson’s institutional review
board guidelines.
Data collection
During the data collection phase, two members of the
research team worked independently: one reviewed
patients’ electronic medical records, and the other
audited and checked the accuracy of the collected
data. Any data discrepancy was resolved by a consen-
sus after group discussion. The collected clinical in-
formation included race, treatment history (e.g.,
surgery, radiation therapy, and chemotherapy), date of
birth, Eastern Cooperative Oncology Group perform-
ance status at the initial phase I clinic visit, mutation
profile of the tumor specimen, phase I clinical trial
therapies, and clinical outcomes (progression-free sur-
vival [PFS], overall survival [OS], and objective re-
sponses, including complete remission [CR], partial
response [PR], and stable disease for 6 months or
longer [SD ≥6 months]).
Clinical objective responses were evaluated using
Response Evaluation Criteria in Solid Tumors software
version 1.0 or 1.1, per individual study protocols [16, 17].
The PFS duration was defined as the interval from the
date of initial treatment to the first objective documenta-
tion of disease progression, the time of death, or the last
date of contact (August 8, 2014), at which time the
patients’ data were censored. OS duration was estimated
from the date of the initial phase I clinical trial therapy to
death or the last date of contact. The enrollment of
eligible patients into specific phase I trials was dependent
on trial availability at the time of presentation and the
preference of the treating physician, according to good
clinical practice. If a phase I agent was unsuccessful,
another was used as long as the patient was eligible and
willing to participate.





Median age, years (range) 60 (30 to 85) 55 (33 to 78)
Race, n (%)
White 13 (81 %) 19 (95 %)
Black 1 (6 %) 0
Hispanic 2 (13 %) 0
Asian 0 1 (5 %)
Body Mass Index, n (%)
Underweight (<18.5) 0 1 (5 %)
Normal Weight (18.5 to 25) 10 (62 %) 13 (65 %)
Overweight (>25) 6 (38 %) 6 (30 %)
The Eastern Cooperative Oncology Group Performance Status, n (%)
0 4 (25 %) 0
1 9 (56 %) 18 (90 %)
2 3 (19 %) 2 (10 %)
Prior Chemotherapy
Yes, n (%) 14 (88 %) 16 (80 %)
Median number (range) 2 (0 to 4) 1 (0 to 6)
Prior Radiation Therapy
Yes, n (%) 15 (94 %) 17 (85 %)
Pathological Diagnosis, n (%)
Squamous Cell Carcinoma 7 (44 %) 17 (85 %)
Adenocarcinoma 4 (25 %) 0
Melanoma 3 (19 %) 3 (15 %)
Carcinosarcoma 1 (6 %) 0
High-grade neuroendocrine carcinoma 1 (6 %) 0
Phase I Trial Enrollment, n (%) 11 (69 %) 16 (80 %)
Fig. 1 Kaplan-Meier plots of survival in patients with metastatic
vaginal cancer (n = 16; median, 6.2 months; 95 % CI, 3.7–8.8 months)
and vulvar cancer (n–20; 4.6 months; 3.7–5.5 months)
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Table 2 Major characteristics and clinical outcomes in patients receiving a phase I trial therapy (n = 27)
Age Pathology Prior therapy OS BMI MDACC score Phase I trials PFS CMS46 or Foundation Med
Vaginal cancer
45 A 2 41.9 33.2 1 Bevacizumab and Temsirolimus 1.0 ND
81 S 0 5.8 21.9 0 Gemcitabine and Dasatinib 0.9 ND
61 M 4 2.0 23.0 3 PI3K Inhibitor and Paclitaxel 0.9 ND
59 A 3 4.8 37.8 2 Bevacizumab and Temsirolimus
plus Carboplatin
PFS1 = 1.4 ND
CHK1 Inhibitor PFS2 = 1.5
Erlotinib and Pralatrexate PFS3 = 2.2
53 S 2 12.9 18.6 0 Aurora Kinase Inhibitor 4.9 ND
57 S 1 1.8 22.9 2 Trientine and Carboplatin 0.7 PIK3CA (E545K)
57 S 0 28+ 21.3 1 Everolimus and Pazopanib PFS1 = 18.2 PIK3CA (E545K), PTPRD (S1845fs*2) and
STK11 loss
PI3K Inhibitor PFS2 = 1.9
72 M 1 4.3 21.0 1 Ipilimumab and Imatinib 2.3 PTEN loss, C17orf39, KDR, KIT and
MYST3 amplification
58 S 1 15+ 19.5 1 Erlotinib and Pralatrexate 14.6+ ERBB2 (S310F), ERBB4 (D609N), FBXW7
(R479Q), RB1 (E539*), ARID2 (Q1194*)
and amplification of EPHBI, PIK3CA
and SOX2
67 A 2 8.4 31.3 1 Anastrozole and Everolimus 2.6 PTEN (210-1G > A), KRAS (G12V), CTNNB1
(D32N), MPL (P106L), and amplification
of MCL1, MYC and NFKB1A
52 S 1 7.1 24.0 0 Erlotinib and Valproic Acid 2.8 ND
Vulvar cancer
37 S 1 3.7 21.2 2 PI3K inhibitor plus Caboplatin
and Paclitaxel
PFS1 = 1.4 PIK3CA: mutation not detected
Erlotinib and Valporic acid PFS2 = 0.6





74 S 1 6.4 23.7 1 Microtube Inhibitor 3.1 ND
60 M 6 4.4 22.3 2 PI3K Inhibitor 2.0 Single Gene: c-KIT (L576P)
42 S 1 2.0 23.7 1 Bevacizumab and Trastuzumab
plus Lapatinib
0.7 ND
42 S 0 1.5 19.9 2 Src Inhibitor 0.5 ND
78 S 0 20.3 35.5 1 Erlotinib and Valporic Acid 6.1 ND
37 S 1 1.7 18.7 2 Camptothecin 0.8 ND
55 S 3 4.8 15.8 1 Histone Deacetylase Inhibitor 0.5 ND
41 S 0 2.2 18.8 2 Sirolimus and Docetaxel 1.7 ND
54 S 1 2.9 26.6 1 Lapatinib and Sirolimus 1.5 Single Gene: BRAF (V600E)
60 M 2 4.6 22.9 3 Multikinase Inhibitor 2.9 ND
69 S 1 22.6 30.9 2 Carboplatin and Trientine 0.9 A 46-gene panel: no mutation detected
33 S 1 10.0 24.8 2 Lenalidomide and Temsirolimus 1.9 ND
73 S 1 5.6 22.4 2 Crizotinib and Pazopanib 1.6 KRAS (R102T), TET2 (W1198*), TP53
(R248Q), and CDK2NA/B loss
55 M 1 3.4 24.2 2 Translation Initiation Inhibition 1.0 ND
OS overall survival, BMI body mass index, MDACC score the sum of five variables (low serum albumin, high serum lactate dehydrogenase, ECOG performance status
of 1 or higher more than two metastatic sites, and gastrointestinal tumor type), PFS progression-free survival (1, 2, or 3 indicates the first, second, or third line of
phase I trial), * deletion , A adenocarcinoma, S squamous cell carcinoma,
M melanoma, ND not done
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Statistical analyses
Categorical data were described using contingency ta-
bles. Continuously scaled measures were summarized
with descriptive statistical measures (i.e., the median and
the range), whereas PFS and OS rates were estimated
using the Kaplan-Meier method. Patients who were still
alive at the time of data analysis were censored at that
time. Fisher’s exact test was used to assess the associ-
ation between categorical variables. Statistical infer-
ences were based on two-sided tests at a significance
level of p <0.05. Statistical analyses were carried out




This study included 36 consecutive patients with meta-
static vaginal (n = 16) or vulvar (n = 20) cancer who were
evaluated in the phase I clinic at MD Anderson. The ma-
jority of these patients were white (n = 32 [89 %]); pre-
sented with squamous cell carcinoma (n = 24 [67 %]); had
adequate functional status, with an Eastern Cooperative
Oncology Group performance status of 0 or 1 (n = 31
[86 %]); and had undergone systemic chemotherapy
(n = 30 [83 %]) or radiation therapy (n = 32 [89 %]).
The patients’ baseline characteristics are listed in
Table 1. All patients had undergone systemic chemo-
therapy or chemoradiation therapy for locally ad-
vanced or metastatic disease before they were referred.
Most patients (n = 27 [75 %]) were enrolled in a phase I
trial.
Major clinical outcomes
The 36 patients had a median OS duration of 5.6 months
(95 % CI, 3.7–7.5 months). A similar duration was
observed in patients with vaginal cancer (6.2 months;
3.7–8.8 months) and vulvar cancer (4.6 months; 3.7–
5.5 months (p = 0.18), as shown in Fig. 1.
The baseline demographics, major clinical outcomes,
and molecular aberrations of the 27 patients who under-
went phase I trial therapy, are listed in Table 2, associ-
ated with a median OS duration of 5.6 months (95 % CI,
3.1–8.1 months). There was no difference in the median
OS duration between patients with vaginal cancer
(7.1 months; 3.2–11 months) and vulvar cancer
(4.4 months; 2.6–6.2 months; p = 0.1), as shown in Fig. 2.
In this cohort of patients who underwent phase I trial
therapy, six (22 %) were classified as obese (BMI ≥30),
one (4 %) overweight (BMI 25–30), 19 (70 %) normal
(BMI 18.5–25), and one (4 %) underweight (BMI <18.5).
Obese patients had a median OS duration of 13.2 months
(95 % CI, 0–27.5 months), which was significantly longer
than that of those who were not obese (4.4 months;
3.1–5.7; p = 0.04), as shown in Fig. 3.
Exploratory molecular analysis
Molecular marker studies were performed of available
tumor specimens in a Clinical Laboratory Improvement
Amendments-certified molecular diagnostic laboratory.
Table 3 lists the limited molecular aberrations per tumor
type. In patients with metastatic vaginal cancer, the
PI3K/AKT/mTOR pathway was activated, which was
supported by the finding of frequent PIK3CA mutations
and PTEN loss or mutation. A loss of STK11 and
FBXW7 mutations was also observed in these patients.
Furthermore, treatment with everolimus and pazopanib
led to a partial response for 18.2 months in one pa-
tient with metastatic squamous cell carcinoma that
harbored PIK3CA (E545K), PTPRD (S1845fs*2), and
STK11 losses.
Fig. 2 Kaplan-Meier plots of survival in patients with metastatic
vaginal cancer (n = 11; median, 7.1 months; 95 % CI, 3.2–11 months)
and vulvar cancer (n = 16; 4.4 months; 2.6–6.2 months) who
underwent phase I trial therapy
Fig. 3 Kaplan-Meier plots of survival in patients with metastatic vaginal
or vulvar cancer and a body mass index (BMI) of ≥30 (n = 6; median,
13.2 months; 95 % CI, 0–27.5 months). These patients survived
significantly longer than did those whose BMI was <30 (n = 21;
4.4 months; 3.1–5.7 months) (p = 0.04)
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Treatment with erlotinib and pralatrexate resulted in
stable disease for approximately 15 months in a patient
with metastatic squamous cell carcinoma that harbored
ERBB2 (S310F), ERBB4 (D609N), FBXW7 (R479Q), RB1
(E539*), and ARID2 (Q1194*) and amplification of
EPHBI, PIK3CA, and SOX2. In patients with metastatic
vulvar cancer, we found no common intracellular
transduction pathway mutations; rather, mutations were
found in TP53, c-KIT, BRAF, and KRAS. One patient
with metastatic KRAS wild-type squamous cell carcin-
oma experienced stable disease for about 11 months
after being treated with epithelial growth factor
inhibition-based phase I trial regimens, while another
patient had stable disease for 6 months after being
treated with erlotinib and valproic acid.
Discussion
Patients with metastatic or recurrent vaginal or vulvar
cancer have limited therapeutic treatment options
[18–20]. In this study, we found that these patients
did not experience a meaningful clinical benefit from
novel phase I therapeutics: there were low rates of
objective responses and a median OS duration of only
5.6 months. Further evaluation is warranted to determine
the effects of novel cancer therapeutics, molecular profil-
ing, and targeted therapy on patient outcomes in the
phase I setting.
There were several notable observations in our study.
In general, patients with metastatic vaginal squamous
cell carcinoma had a median OS duration of 7.1 months
compared with 4.4 months in those with metastatic vul-
var squamous cell carcinoma. Both cohorts of patients
had poor clinical outcomes and low antitumor activity in
response to currently available phase I agents. These pa-
tients had significantly shorter OS durations than did
other patients with other metastatic or recurrent solid
tumors [21–23]. Second, patients with metastatic vaginal
cancer had a higher prevalence of PI3K/AKT/mTOR
pathway activation, while patients with metastatic vulvar
cancer had no common transduction pathway muta-
tions. Therefore, early molecular profiling is urgently
required to further explore therapeutic options for these
patients. Third, since the association between obesity
and survival in patients with metastatic gynecological
malignancies remains equivocal, we determined the
relationship between BMI and major clinical outcomes.
Patients with BMIs of ≥30 had a significantly longer
median OS duration (13.2 months) than did those with
BMIs <30 (4.4 months), suggesting that further studies
are warranted of the effects of excess body weight on
tumor biology. Elucidating the molecular mechanisms of
vaginal and vulvar cancer may result in the development
of more effective therapeutic strategies [24, 25].
A limited sample size was available for subgroup ana-
lyses, which confounded our ability to validate statistical
significance in the category assessment. Nevertheless,
the findings of this retrospective study should be
considered preliminary evidence for generating hy-
potheses that will require further validation in larger
prospective studies.
Conclusion
In conclusion, metastatic vaginal and vulvar cancers are
difficult-to-treat diseases with poor clinical outcomes.
The currently available phase I trial agents provided
little meaningful clinical benefits. Preliminary data re-
vealed differences in molecular profiling between pa-
tients with advanced vaginal cancer and those with
advanced vaginal cancer. Therefore, we advocate the
earlier use of molecular profiling to obtain a better
understanding of their tumorigenesis and development.
Biomarker-driven therapies based on complex molecular
profiles may be an initial step to develop effective thera-
peutic regimens treating these malignancies.
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Table 3 Summary of molecular aberrations per tumor type
Vaginal cancer, n (%) Vulvar cancer, n (%)
PIK3CA 33 % (n = 9) 0 % (n = 8)
PTEN 67 % (n = 6) 0 % (n = 4)
KRAS 10 % (n = 10) 13 % (n = 8)
NRAS 10 % (n = 10) 0 % (n = 4)
EGFR 0 % (n = 9) 0 % (n = 6)
BRAF 0 % (n = 9) 14 % (n = 7)
C-MET 0 % (n = 7) 0 % (n = 3)
TP53 0 % (n = 6) 33 % (n = 3)
C-KIT 0 % (n = 8) 20 % (n = 3)
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